The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications
Overview
Authors
Affiliations
Friedreich's Ataxia is the most common inherited ataxia in man. It is a mitochondrial disease caused by severely reduced expression of the iron binding protein, frataxin. A large GAA triplet expansion in the human FRDA gene encoding this protein inhibits expression of this gene. It is inherited in an autosomal recessive pattern and typically diagnosed in childhood. The primary symptoms include severe and progressive neuropathy, and a hypertrophic cardiomyopathy that may cause death. The cardiomyopathy is difficult to treat and is frequently associated with arrhythmias, heart failure, and intolerance of cardiovascular stress, such as surgeries. Innovative approaches to therapy, such as histone deacetylase inhibitors, and enzyme replacement with cell penetrant peptide fusion proteins, hold promise for this and other similar mitochondrial disorders. This review will focus on the basic findings of this disease, and the cardiomyopathy associated with its diagnosis.
Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment.
Fuertes Kenneally L, Garcia-Alvarez M, Feliu Rey E, Garcia Barrios A, Climent-Paya V Rev Cardiovasc Med. 2024; 23(6):192.
PMID: 39077169 PMC: 11273868. DOI: 10.31083/j.rcm2306192.
Chang J, Ryan M, Stark M, Liu S, Purushothaman P, Bolan F Mol Ther Methods Clin Dev. 2024; 32(1):101193.
PMID: 38352270 PMC: 10862410. DOI: 10.1016/j.omtm.2024.101193.
Mitochondrial Iron Metabolism: The Crucial Actors in Diseases.
Duan G, Li J, Duan Y, Zheng C, Guo Q, Li F Molecules. 2023; 28(1).
PMID: 36615225 PMC: 9822237. DOI: 10.3390/molecules28010029.
Role of Iron-Related Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Diseases.
Yan F, Li K, Xing W, Dong M, Yi M, Zhang H Oxid Med Cell Longev. 2022; 2022:5124553.
PMID: 36120592 PMC: 9473912. DOI: 10.1155/2022/5124553.
Friedreich ataxia: clinical features and new developments.
Keita M, McIntyre K, Rodden L, Schadt K, Lynch D Neurodegener Dis Manag. 2022; 12(5):267-283.
PMID: 35766110 PMC: 9517959. DOI: 10.2217/nmt-2022-0011.